The appearance of Yuhan Corporation's Central Research Institute in Yongin, Gyeonggi Province. Yuhan Corporation, which produced the first domestically developed anticancer drug approved by the FDA last year, ‘Lecarea’, is currently exploring the next blockbuster drug based on continuous R&D investment. /Courtesy of Yuhan Corporation

Yuhan Corporation announced on the 22nd that it signed a contract with the U.S. pharmaceutical company Gilead Sciences on the 21st to supply additional active pharmaceutical ingredients (APIs) for human immunodeficiency virus (HIV) treatments.

The size of the contract is approximately 88.8 billion won, which is about 4.3% of the sales revenue. The contract period is until December 31 of next year.

Earlier, Yuhan Corporation initially signed a contract with Gilead last September to supply active pharmaceutical ingredients for HIV treatments valued at 107.6 billion won.